Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maju Mathews

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Depression and Anxiety|April 21, 2015
A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderCarl Gommoll, Suresh Durgam, Maju Mathews, et al.
Neuropsychiatric Disease and Treatment|December 9, 2021
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled TrialsStephane Borentain, David Williamson, Ibrahim Turkoz, et al.
The Journal of Clinical Psychiatry|May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose TrialSuresh Durgam, Carl Gommoll, Giovanna Forero, et al.
International Journal of Clinical Practice|May 1, 2018
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulationsAlberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, et al.
Comprehensive Psychiatry|March 12, 2021
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitateRebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, et al.
Neuropsychiatric Disease and Treatment|December 1, 2018
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitateMaju Mathews, Isaac Nuamah, Adam J Savitz, et al.
The American Journal of Psychiatry|April 1, 2005
Child psychopharmacology, effect sizes, and the big bangMaju Mathews, Babatunde Adetunji, Joanne Mathews, et al.
The American Journal of Psychiatry|September 27, 2017
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I DisorderArmin Szegedi, Suresh Durgam, Mary Mackle, et al.
International Clinical Psychopharmacology|March 2, 2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophreniaArun Singh, Srihari Gopal, Edward Kim, et al.
The Lancet. Psychiatry|February 24, 2020
Approval of esketamine for treatment-resistant depressionJaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Depression and Anxiety|April 21, 2015
A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderCarl Gommoll, Suresh Durgam, Maju Mathews, et al.
Neuropsychiatric Disease and Treatment|December 9, 2021
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled TrialsStephane Borentain, David Williamson, Ibrahim Turkoz, et al.
The Journal of Clinical Psychiatry|May 28, 2016
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose TrialSuresh Durgam, Carl Gommoll, Giovanna Forero, et al.
International Journal of Clinical Practice|May 1, 2018
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulationsAlberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, et al.
Comprehensive Psychiatry|March 12, 2021
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitateRebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, et al.
Neuropsychiatric Disease and Treatment|December 1, 2018
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitateMaju Mathews, Isaac Nuamah, Adam J Savitz, et al.
The American Journal of Psychiatry|April 1, 2005
Child psychopharmacology, effect sizes, and the big bangMaju Mathews, Babatunde Adetunji, Joanne Mathews, et al.
The American Journal of Psychiatry|September 27, 2017
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I DisorderArmin Szegedi, Suresh Durgam, Mary Mackle, et al.
International Clinical Psychopharmacology|March 2, 2018
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophreniaArun Singh, Srihari Gopal, Edward Kim, et al.
The Lancet. Psychiatry|February 24, 2020
Approval of esketamine for treatment-resistant depressionJaskaran B Singh, Ella J Daly, Maju Mathews, et al.
Pageof 10